In this post we're going to be taking a look at some of the biggest losers during this correct and picking out the ones with the highest potential rebound based on some fundamentals about the project.

Criteria for my selections

1. Projects have to be unique, unexplored, or simply do the job better than the rest. This is a golden rule in my book. You really shouldn't be (long-term) holding projects that have similar visions. There is almost ALWAYS a better of the choices. For example: If you want to hold a currency - weigh the benefits of some of the top picks and pick ONE. Nano, BCash, Litecoin, etc.

2. Projects need to have a solid vision and roadmap. This is business 101. I'm never going to suggest a project for long-term holds that don't even know where they are going. A change of vision is absolutely fine, but a weak vision absolutely is NOT.

3. An ATH, significantly higher than its current price, and based on true supply/demand. In other words, I won't be including obvious pump/dump coins. There are tons of amazing coins out there that are a solid purchase right now - but I will be sticking to a few that have taken the correct....a little too hard.

Let's get on with it. I will disclose my holdings (in any) in these coins. These picks will be ranked appropriately, according to my review.

1. EncrypGen (DNA) - $0.39, 80% loss from ATH:

"The Gene-Chain is a blockchain (a cryptographically encoded ledger) to mediate the searching, storing, buying and selling of genomic data."

DNA has been kind of a sleeper in general, but it's definitely a solid choice right now. Sitting at just barely a 25m mcap this project aims to bring the blockchain to genomic data. Their ultimate vision is to have multiple different parties (labs) buying right to this genomic data. They recently have partnered with Sequencing.com, Codigo46, Health Wizz, Car Tek Bio, and Genomics Personalized Health (GPH).

These guys have been making extremely solid progress in both their road map and vision. This is one of the few projects utilizing HEALTH data on the blockchain and this is a HUGE market. Healthcare is both highly regulated and technology-embracing. I expect a big push for healthcare/healthcare data centered blockchain projects as blockchain gains legitimacy.

In a post by /u/RubyRedDeath he did a good job explaining a scenario for DNA

Encrypgen attempts to create a global marketplace of Institutional requesters (universities, hospitals, scientists, etc…) of sequenced DNA, and providers of sequenced DNA. Also, any person can be a provider of sequenced DNA, and be rewarded for their contribution. Researchers around the globe will use DNA coins to pay for access to study that genomic data. Patients can also do this and get rewarded. Each provider will be able to upload their sequenced genomic data, and choose the metadata that they wish to reveal or expose to researchers for their reward of DNA coins.

I have held DNA in the past - I solid near ATH during a portfolio re-balancing. I would not be opposed to buying more.

2. Simple Token (OST) - $0.33, 77% loss from ATH:

Simple token, put simply, is bringing blockchain to the masses. They are making it easy to implement your own blockchain/tokens without the hassle.

This is a great example of their vision/goals for use in the real-world: https://www.youtube.com/watch?time_continue=1&v=-SxJ8c1Xh_A

The team at Simple Token is really making things easy for their consumer. They continually release a series of simple solutions that will enable startups to really FLY through the process. Very recently they introduced 'Lyte pay' which making managing payment and invoice very easy. Additionally they have, ostKYC - making the KYC (Know your customer) process more more streamlined and easy.

They have a number of partners, that I won't go into, but just reiterate that the establishment of meaningful customers is SO important for growth. Keep an eye on these guys.

I do not own SimpleToken

3. ICON (ICX) - $5.28, 58% loss from ATH

Icon is a platform, similar to NEO or ETH who has a focus on connectivity. They want to connect all sorts of platforms including BTC, ETH, ARK, etc. Their platform has a number of 'upgrades' to the traditional blockchain platform such as unique nicknames in place of an address, inter-connectivity, icon tracker, etc.

ICON recently has had a bit of 'sell the news' action which had propelled it's price a bit further than the rest of the market. ICON is currently on its mainnet and seems to be meeting development goals. In my opinion, ICON's biggest perk is that it's in a 'trifecta alliance' with AION and Wanchain. The combined efforts of their goals and vision would lead to an extraordinary dominance over the market. Notable partners include forbes, bloomberg, coinone, universities, Woori Bank, SBI, and samsung securities.

Time will tell, but ICON is poising themselves for future success.

I do own a small portion of ICX in my portfolio

4. AChain (ACT) - $0.39, 78% loss from ATH.

Achain is a public blockchain platform that enables developers of all levels of experience to issue tokens, smart contracts, create applications and blockchain systems.

Achain is encouraging forks off their platform. For such little hype, Achain's platform is impressive. 1,000 transactions per second and RDPOS. This is an advanced platform, given our current advancements in blockchain, and the teams wants people to utilize their network via forks. Making it easier for ICOs and startups to have a platform that is both advanced and encouraging of collaboration targets a big market.

There are numerous incentives for investors because not only do you receive rewards from the POS, but you also receive a 1:1 ratio of the forked coins - which built on the Achain blockchain could become fairly successful.

I have owned AChain in the past

So those are my picks for what I would choose in times like these. Solid tech and vision with the means to see it through. I believe these projects could excel, in 2018, along with a strong recovery from their current price. As always, I'm not a financial adviser.

What are YOUR top picks during this correction?